Promising Efficacy of Biomea Fusion's BMF-219 in Type 1 Diabetes Treatment: A Positive Outlook on Early Clinical DataTipRanks Financial Blog • 23 days ago
Analyst Yigal Nochomovitz of Citi maintained a Buy rating on Biomea Fusion (BMEA Research Report), retaining the price target of $90.00. Yigal No...
Share to Feed
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Humana (HUM Research Report), Baxter International...
Investors eyeing a purchase of Biomea Fusion Inc (BMEA) shares, but cautious about paying the going market price of 13.61/share, might benefit from considering selling puts among the alternative...
REDWOOD CITY, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) ( Biomea or the Company ), a clinical stage biopharmaceutical company focused on the discovery and...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
BMEA stock results show that Biomea Fusion missed analyst estimates for earnings per share the fourth quarter of 2023.
The post BMEA...
Biomea Fusion GAAP EPS of -$0.98...
In 2023, reported Phase 2 data (COVALENT-111) in type 2 diabetes patients supporting the disease-modifying potential of BMF-219 to address a root cause of diabetes: a loss of healthy...
In trading on Thursday, shares of Biomea Fusion Inc (BMEA) crossed above their 200 day moving average of 17.24, changing hands as high as 17.25 per share. Biomea Fusion Inc shares are...
For the last three days, A.I.dvisor has detected that BMEA's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...
For the last three days, A.I.dvisor has detected that BMEA's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...